therapeutics

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company…

10 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…

11 months ago

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

11 months ago

Gain Therapeutics Announces Proposed Public Offering

July 15, 2025 16:36 ET  | Source: Gain Therapeutics, Inc. BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics,…

11 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing…

11 months ago

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

11 months ago

LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net…

11 months ago

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics…

11 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

11 months ago

Akari Therapeutics Releases Virtual Investor What This Means Segment Highlighting its Recently Granted India Patent

June 25, 2025 09:00 ET  | Source: Akari Therapeutics Plc Access the “What This Means” segment here BOSTON and LONDON,…

11 months ago